Clinical trials: Affective Disorder
Bipolar Disorder, Bipolar Depression
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
Bipolar depression is one of the least studied depressive illnesses. The standard practice for many doctors is to use antidepressant medicines, but there are few studies on the long-term results of these medicines.
- Trial name
- NCT00562861
- Testing
- citalopram + mood stabilizer
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Tufts Medical Center
Major Depressive Disorder
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders…
- Trial name
- NCT04985942
- Testing
- Lumateperone
- Where
- 54 sites in United States, Bulgaria and 4 more
- Volunteers
- 485 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder
Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder
In this study, quetiapine XR or placebo will be administered orally for 6 weeks to major depressive disorder patients with lack of response to existing antidepressants, with the aim of evaluating the efficacy of quetiapine XR and…
- Trial name
- NCT01725282
- Testing
- quetiapine extended release (XR)
- Where
- 3 sites in Japan
- Volunteers
- 172 people
- Sponsor
- Astellas Pharma Inc
Major Depressive Disorder
Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)
The purpose of this study is to evaluate the efficacy of vortioxetine (5, 10, and 20 mg) versus placebo during the first 28 weeks of the 32-week double-blind treatment period in the prevention of relapse in participants with MDD…
- Trial name
- NCT02371980
- Testing
- Vortioxetine
- Where
- 79 sites in United States
- Volunteers
- 1,106 people
- Sponsor
- Takeda
Depression, Postpartum Depression
Personalized Integrated Chronotherapy for Perinatal Depression
Perinatal depression and anxiety are common, serious, and frequently overlapping disorders that increase morbidity and mortality in new mothers (including suicide) and result in poor infant/child outcomes.
- Conditions
- Depression, Postpartum Depression, Prenatal Disorder, Circadian Dysregulation
- Trial name
- NCT04364646
- Testing
- Personalized Integrated Chronotherapy
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Rhode Island Hospital
Major Depressive Disorder
Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms
Studies of the neural mechanisms underlying placebo effects in antidepressant clinical trials largely have been limited to demonstrating objective differences in brain activity between responders and non-responders to placebo.
- Trial name
- NCT01919216
- Testing
- Citalopram
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Depression
Imaging Biomarkers for TMS Treatment of Depression
The purpose of this research is to learn more about how rTMS works to reduce the symptoms of depression. This information can be used to improve the effectiveness of the treatment.
- Trial name
- NCT01900314
- Testing
- repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan
Bipolar Disorder
Project CARE: An Integrated Treatment Adherence Program for Bipolar Disorder at the Time of Prison Release - Open Trial
The aim of this program of research is to develop and pilot the CARE (Community treatment Adherence at Re-Entry) program, an adjunctive intervention for incarcerated individuals with bipolar disorder (BD) transitioning from…
- Trial name
- NCT03825640
- Testing
- CARE
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Brown University
Migraine, Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
The primary objective is to evaluate the efficacy of monthly 225 mg sc fremanezumab in adult participants with migraine and major depressive disorder (MDD) The secondary objectives are to evaluate the efficacy of monthly 225 mg…
- Trial name
- NCT04041284
- Testing
- Fremanezumab
- Where
- 64 sites in United States, Czechia and 11 more
- Volunteers
- 353 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Major Depressive Disorder
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
This study will evaluate the efficacy of ALKS 5461 when administered daily for 4 weeks to adults with Major Depressive Disorder (MDD) and inadequate response to antidepressant therapy.
- Trial name
- NCT01500200
- Testing
- ALKS 5461
- Where
- 27 sites in United States
- Volunteers
- 142 people
- Sponsor
- Alkermes, Inc.
Bipolar Disorder, Obesity
Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)
Taken together these data support the hypothesis that liraglutide 3.0 mg sc injection will reduce body weight and improve metabolic variables in obese or overweight patients with BP without worsening psychiatric symptoms.
- Trial name
- NCT03158805
- Testing
- LIRAGLUTIDE
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Lindner Center of HOPE
Schizophrenia, Schizoaffective Disorder
Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
The objective of this study is to determine the effect of various mood stabilizers (MS) on the insulin resistance syndrome (IRS; also called the metabolic syndrome) alone and in patients treated with antipsychotic drugs (APDs).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00288366
- Testing
- ziprasidone vs. aripiprazole, aripiprazole vs. ziprasidone
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Northwestern University
Bipolar Depression
Minocycline for Bipolar Depression
The purpose of this study is to evaluate minocycline as a potential treatment for bipolar depression when added to a mood-stabilizing medication.
- Trial name
- NCT01514422
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Seasonal Affective Disorder
30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder
The primary objective of this study is to evaluate the effect of light therapy using a narrow 467nm light compared to a 580nm light in subjects with Seasonal Affective Disorder (SAD).
- Trial name
- SAD (NCT01462305)
- Testing
- goLITE, Control
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Philips Respironics
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy of switching adult participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to flexibly dosed intranasal…
- Trial name
- NCT03434041
- Testing
- Esketamine 56 mg, Esketamine 84 mg, Duloxetine (Oral Antidepressant)
- Where
- 30 sites in United States, China
- Volunteers
- 252 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder, Menopause
A Neurosteroid Intervention for Menopausal and Perimenopausal Depression
HYPOTHESIS: Pregnenolone administration will be associated with greater reduction in depressive symptom severity than placebo in women with current mMDD.
- Conditions
- Major Depressive Disorder, Menopause, Perimenopause
- Trial name
- NCT03505905
- Testing
- Pregnenolone
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetic Neuropathies, Depressive Disorder, Major
Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder
The primary objective is to evaluate, separately in diabetic polyneuropathic pain (DPNP) patients with and without co-morbid major depressive disorder (MDD), whether duloxetine given as 60 mg to 120 mg once daily (QD) leads to a…
- Trial name
- NCT00844194
- Testing
- Duloxetine 60 mg QD, Duloxetine 30 mg QD, Duloxetine 90 mg QD
- Where
- 25 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Depressive Disorder, Major
A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to placebo in adult patients with major depressive disorder (MDD) who are at imminent risk of suicide.
- Trial name
- NCT03352453
- Testing
- Rapastinel
- Where
- 17 sites in United States
- Volunteers
- 138 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Schizophrenia, Bipolar Disorder
Person-Centered Versus Measurement-Based Care in Mental Health
Fifteen minutes is the typical length of an outpatient medication management appointment for people with serious mental health conditions.
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depression
- Trial name
- PCORI-SDM (NCT02507349)
- Testing
- Person-Centered Care, Measurement-Based Care
- Where
- 2 sites in United States
- Volunteers
- 2,443 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Medication Nonadherence
Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)
The proposed, three phase project will refine and test a first-ever care approach in SSA that combines LAI with a behavioral program specifically intended to promote medication adherence in chronic psychotic disorders (CPDs).
- Conditions
- Schizophrenia, Medication Nonadherence, Schizo Affective Disorder
- Trial name
- CAPACITY (NCT04327843)
- Testing
- Customized Adherence Enhancement, Haloperidol Decanoate
- Where
- Tanzania
- Volunteers
- 22 people
- Sponsor
- Case Western Reserve University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.